Document:

Exhibit 4.6

 

Form of 5.000% Senior Note due 2045

 

GLOBAL SECURITY

 

THIS NOTE IS A GLOBAL SECURITY WITHIN THE
MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY.
THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY,
BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE
TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY. TRANSFERS OF PORTIONS OF THIS GLOBAL SECURITY ARE LIMITED
TO TRANSFERS PERMITTED BY THE INDENTURE.

 

CELGENE CORPORATION

 

5.000% Senior Note due 2045

 

	No.	 	PRINCIPAL AMOUNT
	 	 	$

 

CUSIP: 151020 AU8

ISIN: US151020AU84

 

Celgene Corporation, a Delaware corporation
(herein called the “Company,” which term includes any successor Person under the Indenture hereinafter referred
to), for value received, hereby promises to pay to Cede & Co., or registered assigns, the principal sum set forth in the attached
Schedule of Increases and Decreases in Global Note on August 15, 2045 (the “Maturity Date”) (except to the extent
redeemed or repaid prior to the Maturity Date) and to pay interest thereon from August 12, 2015 (the “Original Issue Date”)
or from the most recent Interest Payment Date to which interest has been paid or duly provided for semi-annually at the rate of
5.000% per annum, on February 15 and August 15 (each such date, an “Interest Payment Date”), commencing February
15, 2016, until the principal hereof is paid or made available for payment.

 

Payment of Interest. The interest
so payable, and punctually paid or made available for payment, on any Interest Payment Date, will, as provided in the Indenture,
be paid, in immediately available funds, to the Person in whose name this Note is registered at the close of business on the February
1 or August 1 (whether or not a Business Day, as defined in the Indenture) as the case may be, next preceding such Interest Payment
Date (the “Regular Record Date”). Any such interest not punctually paid or duly provided for (“Defaulted
Interest”) will forthwith cease to be payable to the Holder on such Regular Record Date, and such Defaulted Interest
may be paid to the Person in whose name this Note is registered at the close of business on a special record date (the “Special
Record Date”) for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to
Holders of Notes not less than ten days prior to such Special Record Date, or may be paid at any time in any other lawful manner
not inconsistent with requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in said Indenture.

 

Place of Payment. Payment of principal,
premium, if any, and interest on this Note will be made at the Corporate Trust Office of the Trustee or such other office or agency
of the Company as may be designated for such purpose, in such currency of the United States of America as at the time of payment
is legal tender for payment of public and private debts; provided, however, that each installment of interest, premium,
if any, and principal on this Note may at the Company’s option be paid in immediately available funds by transfer to an account
maintained by

 

    	 

    	 

    

 

the payee located in the United States of America.

 

Time of Payment. In any case where
any Interest Payment Date, the Maturity Date or any date fixed for redemption or repayment of the Notes shall not be a Business
Day, then (notwithstanding any other provision of the Indenture or this Note), payment of principal or interest, if any, need not
be made on such date, but may be made on the next succeeding Business Day with the same force and effect as if made on such Interest
Payment Date, the Maturity Date or the date so fixed for redemption or repayment, and no interest shall accrue in respect of the
delay.

 

General. This Note is one of a duly
authorized security of the Company, issued and to be issued under an indenture (the “Indenture”), dated as of
August 12, 2015, between the Company and The Bank of New York Mellon Trust Company, N.A. (herein called the “Trustee,”
which term includes any successor Trustee under the Indenture with respect to a series of which this Note is a part). Reference
is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder
of the Company, the Trustee and the Holders of the Notes, and of the terms upon which the Notes are, and are to be, authenticated
and delivered. This Note is one of a duly authorized series of Notes designated as “5.000% Senior Notes due 2045” (collectively,
the “Notes”), initially limited in aggregate principal amount to $2,000,000,000.

 

Further Issuance. The Company may
from time to time, without the consent of the Holders of the Notes, issue additional Securities (the “Additional Securities”)
of this series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities
of this series and the Notes will constitute a single series under the Indenture and all references to the Notes shall include
the Additional Securities unless the context otherwise requires.

 

Events of Default. If an Event of
Default with respect to the Notes shall have occurred and be continuing, the principal of the Notes may be declared due and payable
in the manner and with the effect provided in the Indenture.

 

Sinking Fund. The Notes are not subject
to any sinking fund.

 

Optional Redemption. The Notes will
be redeemable at any time, at the option of the Company, in whole or from time to time in part, upon not less than 30 nor more
than 60 days’ prior notice, on any date prior to their Stated Maturity at a Redemption Price, calculated pursuant to the
Indenture, which includes accrued interest thereon, if any, to, but not including, the Redemption Date. On or after the date that
is six months prior to the Stated Maturity of the Notes, the Notes will be redeemable, in whole, at any time, or in part, from
time to time, at the option of the Company upon not less than 30 nor more than 60 days’ notice at a Redemption Price equal
to 100% of the principal amount thereof plus accrued and unpaid interest to the Redemption Date. In the case of any partial redemption,
selection of the Notes for redemption will be made by lottery or other method in accordance with the applicable procedures of DTC.
If any Note is to be redeemed in part only, the notice of redemption relating to such Note shall state the portion of the principal
amount thereof to be redeemed; provided that the principal amount of any Note remaining outstanding after a redemption in
part shall be $2,000 or a higher integral multiple of $1,000 in excess thereof. A new Note in principal amount equal to the unredeemed
portion thereof will be issued in the name of the Holder thereof upon cancellation of this Note.

 

Special Mandatory Redemption. Within
five Business Days following the earlier of (i) the date on which an Acqusition Termination Event occurs and (ii) July 14, 2016,
if the Acquisition has not closed on or prior to such date, the Company shall be required to mail a notice of mandatory redemption
to the Holders of the Notes fixing the Special Mandatory Redemption Date. On such Special Mandatory Redemption Date, the Company
shall be required to redeem the Notes, in whole but not in part, at the Special Mandatory Redemption Price.

 

Repurchase upon a Change of Control Triggering
Event. Upon the occurrence of a Change of Control Triggering Event with respect to the Notes, the Company shall be required
to make an offer to repurchase the Notes on the terms set forth in the Indenture.

 

Restrictive Covenants. The Indenture
contains certain covenants that, among other things, limit the ability of the Company and its Subsidiaries to create liens or the
ability of the Company to consolidate, merge or sell, transfer or lease all or substantially all of its assets.

 

Defeasance and Covenant Defeasance.
The Indenture contains provisions for defeasance at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related defaults and Events of Default, upon compliance by the Company with certain conditions
set forth therein, which provisions apply to this Note.

 

Modification and Waivers; Obligations
of the Company Absolute. The Indenture permits, with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the Holders of the Notes of any series. Such amendment
may be effected under the

 

    	 

    	 

    

 

Indenture at any time by the Company, and the Trustee with the
consent of the Notes of not less than a majority in aggregate principal amount of the outstanding Notes of such series affected
thereby. The Indenture also contains provisions permitting the Holders of not less than a majority in aggregate principal amount
of the Notes at the time outstanding, on behalf of the Holders of all outstanding Notes, to waive compliance by the Company with
certain provisions of the Indenture. Furthermore, provisions in the Indenture permit the Holders of not less than a majority in
aggregate principal amount of the outstanding Notes of individual series to waive on behalf of all of the Holders of Notes of such
individual series certain past defaults under the Indenture and their consequences. Any such consent or waiver shall be conclusive
and binding upon the Holder of this Note and upon all future Holders of this Note and of any Note issued upon the registration
of transfer hereof or in exchange hereof or in lieu hereof, whether or not notation of such consent or waiver is made upon this
Note.

 

No reference herein to the Indenture and
no provision of this Note or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional,
to pay the principal of and interest on this Note at the time, place, and rate, and in the currency, herein prescribed.

 

No Recourse Against Others. No director,
officer, agent, employee, incorporator, stockholder, partner, member, or manager of the Company shall have any liability for any
obligations of the Company under any Notes, the Indenture or for any claim based on, in respect of, or by reason of, such obligations
or their creation. Each Holder of the Notes by accepting a Note waives and releases all such liability. The waiver and release
are part of the consideration for issuance of the Notes.

 

Limitation on Suits. As set forth
in, and subject to, the provisions of the Indenture, no Holder of any Note will have any right to institute any proceeding with
respect to the Indenture or for any remedy thereunder, unless such Holder shall have previously given to the Trustee written notice
of a continuing Event of Default with respect to this series, the Holders of a majority in principal amount of the outstanding
Notes shall have made written request to the Trustee, and offered indemnity satisfactory to the Trustee, to institute such proceedings
as Trustee, and the Trustee shall not have received from the Holders of a majority in principal amount of the outstanding Notes
a direction inconsistent with such request and shall have failed to institute such proceeding within 60 days; provided,
however, that such limitations do not apply to a suit instituted by the Holder hereof for the enforcement of payment of
the principal of or interest on this Note on or after the respective due dates expressed herein.

 

Authorized Denominations. The Notes
are issuable only in registered form without coupons in minimum denominations of $2,000 or a higher integral multiple of $1,000
in excess thereof.

 

Registration of Transfer or Exchange.
As provided in the Indenture and subject to certain limitations herein and therein set forth, the transfer of this Note is registrable
in the register of the Notes maintained by the Registrar upon surrender of this Note for registration of transfer, at the office
or agency of the Company in any place where the principal of and interest on this Note are payable, duly endorsed by, or accompanied
by a written instrument of transfer in form satisfactory to the Company and the Registrar, duly executed by the Holder hereof or
his attorney duly authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate
principal amount, will be issued to the designated transferee or transferees.

 

As provided in the Indenture and subject
to certain limitations herein and therein set forth, the Notes are exchangeable for a like aggregate principal amount of Notes
of different authorized denominations, as requested by the Holders surrendering the same.

 

No service charge shall be made for any
such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental
charge payable in connection therewith.

 

Prior to due presentment of this Note for
registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Holder as the owner
hereof for all purposes (except with respect to certain payments of Defaulted Interest), whether or not this Note be overdue, and
neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary.

 

Defined Terms. All terms used in
this Note, which are defined in the Indenture and are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

 

Governing Law. This Note shall be
governed by and construed in accordance with the laws of the State of New York.

 

Unless the certificate of authentication
hereon has been executed by the Trustee by manual signature, this Note shall not be entitled to any benefit under the Indenture
or be valid or obligatory for any purpose.

 

[Remainder of page intentionally left
blank]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed and attested.

 

Dated: August 12, 2015

 

	 	CELGENE CORPORATION, as the Company
	 	 
	 	By: 	 
	 	Name:
	 	Title:

 

	
        Attest:

         
	 
	By: 	 	 
	Name:	 
	Title:	 
	 	 	 

 

    	 

    	 

    

 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

 

This is one of the Notes of the series designated
therein referred to in the within-mentioned Indenture.

 

	 	THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as Trustee
	 	 
	 	By: 	 
	 	 	Authorized Signatory
	 	 
	 	Dated: August 12, 2015

 

    	 

    	 

    

 

ASSIGNMENT FORM

 

I or we assign and transfer this Note to

 

	 
	 
	 

(Print or type name, address and zip code of assignee or transferee)

 

	 

(Insert Social Security or other identifying number of assignee
or transferee)

 

and irrevocably appoint _________________________________________________
agent to transfer this Note on the books of the Company. The agent may substitute another to act for him.

 

	Dated:	 	 	Signed: 	 
	 	 	 
	 	 	(Sign exactly as name appears on the other side of this Note)

 

	Signature Guarantee:	 
	 	Participant in a recognized Signature Guarantee Medallion
	 	Program (or other signature guarantor program reasonably acceptable to the Trustee)

 

    	 

    	 

    

 

SCHEDULE OF INCREASES AND DECREASES IN GLOBAL
NOTE

 

Celgene Corporation

 

5.000% Senior Note due 2045

 

The initial principal amount of this Global
Note is $___________. The following increases or decreases in this Global Note have been made:

 

	Date 
		Amount of

                                         decrease in

                                         Principal Amount

                                         of this Global

                                         Note
		Amount of

                                         increase in

                                         Principal Amount

                                         of this Global

                                         Note
		Principal Amount

                                         of this Global

                                         Note following

                                         such decrease or

                                         increase
		Signature of

                                         authorized

                                         signatory of

                                         Trustee or Note

                                         CustodianLICENSE
AGREEMENT

 

THIS
LICENSE AGREEMENT (this “Agreement”) dated as of August 11, 2015 (the “Effective Date”), is entered into
between IMPRIMIS PHARMACEUTICALS, INC., a Delaware corporation (“Imprimis”), having a place of business at 12264 El
Camino Real, Suite 350, San Diego, California 92130, U.S.A., on the one hand, and ADVANCED DOSAGE FORMS, INC., a Canadian corporation
(“ADF”), having a place of business at 3700 St-Patrick, suite 240, Montreal, Quebec, H4E 1A2, Canada, and JOHN DIGENOVA,
an individual (“DiGenova”, and together with ADF, collectively, the “ADF Parties”), on the other hand.
The parties hereby agree as follows:

 

	 	1.	DEFINITIONS.

 

For
the purposes of this Agreement, the following terms shall have the respective meanings set forth below:

 

1.1“Affiliate”
shall mean, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under
common control with, such Person. A Person shall be regarded as in control of another Person if it owns, or directly or indirectly
controls, more than fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly
or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means
whatsoever.

 

1.2“Challenge”
shall mean, with respect to any patent rights, directly or indirectly, (a) to assert in any court, patent office or other competent
governmental authority that such patent rights are invalid or unenforceable in whole or in part, (b) to oppose the issuance of,
or to challenge or seek to narrow the issued or applied for claims, scope or duration of, any claim of such patent rights, (c)
to seek a declaratory judgment or similar relief that any product or service does not infringe any such patent rights or is licensed
or otherwise authorized under this Agreement or otherwise, (d) to seek, request or otherwise take any action that results in the
declaration, initiation or continuation of an interference or derivative proceeding, opposition, reexamination, post-grant review
or inter partes review (or their equivalents) of such patent rights, or (e) to assist or cooperate with any other Person to do
any of the foregoing.

 

1.3“Confidential
Information” shall mean, with respect to a party, all information and data that (a) is provided by or on behalf of such
party to the other party under this Agreement, and if disclosed in writing or other tangible medium is marked or identified as
confidential at the time of disclosure to the recipient, is acknowledged at the time of disclosure to be confidential, or otherwise
should reasonably be deemed to be confidential, or (b) is derived by the recipient from the observation or use of the foregoing.
Notwithstanding the foregoing, Confidential Information of a party shall not include that portion of such information and data
which, and only to the extent, the recipient can establish by written documentation: (i) is known to the recipient as evidenced
by its written records before receipt thereof from the disclosing party, (ii) is disclosed to the recipient free of confidentiality
obligations by a third person who has the right to make such disclosure, (iii) is or becomes part of the public domain through
no fault of the recipient, or (iv) the recipient can reasonably establish is independently developed by persons on behalf of the
recipient without access to or use of the information disclosed by the disclosing party.

 

    	1

    	 

    

  

1.4“Field”
shall mean the prevention or treatment of any ophthalmic disease, state or condition in humans.

 

1.5“First
Commercial Sale” shall mean, with respect to a Product, the first sale of such Product by ADF, its sublicensees or their
respective Affiliates to customers who are not Affiliates in the Territory.

 

1.6“Imprimis
In-License” shall mean a license, sublicense or other agreement under which Imprimis has acquired, or hereafter acquires,
rights to the Licensed IP Rights.

 

1.7“Licensed
Copyrights” shall mean, collectively, Imprimis’ rights in those certain copyrights in the Territory and copyrightable
works (including without limitation all rights of authorship, use, publication, reproduction, distribution, performance, transformation,
moral rights and rights of ownership of copyrightable works and all rights to register and obtain renewals and extensions of registrations,
together with all other interests accruing by reason of international copyright), together with all registrations and applications
therefor in the Territory, in and to the marketing, promotional and other materials relating to the Products or their use in the
Field that are designated from time to time in writing by Imprimis for use by ADF under this Agreement.

 

1.8“Licensed
IP Rights” shall mean, collectively, the Licensed Copyrights, Licensed Know-How Rights, Licensed Marks and Licensed
Patent Rights.

 

1.9“Licensed
Know-How Rights” shall mean, collectively, Imprimis’ rights in all trade secret and other know-how rights reasonably
necessary for the formulation, making or use of the Products in the Territory in the Field.

 

1.10“Licensed
Marks” shall mean Imprimis’ rights in those certain trademarks, trade names, designs and markings, together with
all registrations and applications therefor in the Territory, that are designated from time to time in writing by Imprimis for
use by ADF under this Agreement.

 

1.11“Licensed
Patent Rights” shall mean, collectively, Imprimis’ rights in (a) all patent applications (including provisional
patent applications) in the Territory, together with all divisional, continuation, continuation-in-part and substitute applications
that claim priority to, or common priority with, the foregoing; and (b) all patents in the Territory issuing therefrom (including
utility models, design patents and certificates of invention), together with all extensions, supplementary protection certificates,
registrations, confirmations, reissues, reexaminations, inter partes reviews, post-grant reviews, restorations and renewals
of or to any of the foregoing, in each case that claim, and only to the extent they claim the Products or the formulation, making
or use thereof.

 

1.12“Marketing
Committee” shall mean the committee comprising representatives of Imprimis and ADF, described in Section 6.1 below.

 

    	2

    	 

    

  

1.13“Person”
shall mean any individual, partnership, firm, corporation, association, trust, unincorporated organization or other entity, as
well as any syndicate or group of any of the foregoing.

 

1.14“Products”
shall mean the final dosage and packaged formulations of the products (a) which are specifically described on Exhibit A, as amended
or restated from time to time by mutual written agreement of the parties, and (b) the formulation, making, use, offer for sale
or sale of which in the Territory is claimed or covered by a Valid Claim.

 

1.15“Qualified
Pharmacy” shall mean a compounding pharmacy facility that (a) is owned and operated by ADF or its sublicensed Affiliates,
(b) has been expressly approved in writing in advance by Imprimis, and (c) is in strict compliance at all times with all applicable
laws and regulations.

 

1.16“Royalty
Term” shall mean, with respect to a Product, the term for which the formulation, making, use, offer for sale or sale
thereof in the Territory is claimed or covered by a Valid Claim.

 

1.17“Sales”
shall mean, with respect to a Product, the gross sales price of such Product invoiced by ADF, its sublicensees or their respective
Affiliates to end user customers; provided, however, that Sales shall exclude (a) sales, use, value-added and other direct taxes
incurred on the sale of such Product to such customers that are separately itemized, and (b) discounts, rebates and other price
reductions for such Product given to such customers under price reduction programs that are consistent with price reductions given
for similar products by ADF, its sublicensees or their respective Affiliates (as applicable) and are expressly approved in writing
by Imprimis.

 

1.18“Specifications”
shall mean, with respect to each Product, the specifications for the formulation and making thereof provided by Imprimis from
time to time.

 

1.19“Supported
Patent Rights” shall mean, collectively, (a) all patent applications (including provisional patent applications), together
with all divisional, continuation, continuation-in-part and substitute applications that claim priority to, or common priority
with, the foregoing; and (b) all patents issuing therefrom (including utility models, design patents and certificates of invention),
together with all extensions, supplementary protection certificates, registrations, confirmations, reissues, reexaminations, inter
partes reviews, post-grant reviews, restorations and renewals of or to any of the foregoing, in each case that use or are
supported by data or information derived from the activities under this Agreement.

 

1.20“Territory”
shall mean Canada.

 

1.21“Valid
Claim” shall mean either (a) a claim of an issued and unexpired patent included within the Licensed Patent Rights which
has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent
jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or
unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application included within the Licensed
Patent Rights, which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility of
appeal or refiling of such application.

 

    	3

    	 

    

  

	 	2.	REPRESENTATIONS
    AND WARRANTIES.

 

2.1By
Imprimis. Imprimis represents and warrants to the ADF Parties as follows:

 

2.1.1Organization.
Such party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized.

 

2.1.2Authorization
and Enforcement of Obligations. Such party (a has the requisite power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered
on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with
its terms.

 

2.1.3Consents.
All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to
be obtained by such party in connection with this Agreement have been obtained.

 

2.1.4No
Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a)
do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not
conflict with, or constitute a default under, any contractual obligation of such party.

 

2.2By
the ADF Parties. The ADF Parties represent and warrant to Imprimis as follows:

 

2.2.1Organization.
ADF is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized.

 

2.2.2Competence
and Capacity. DiGenova is an individual, resident of the Province of Québec, Canada, and competent to conduct his affairs
and to enter into and perform his obligations under this Agreement. Curry has the capacity and the legal right to enter into this
Agreement and to perform his obligations hereunder.

 

2.2.3Authorization
and Enforcement of Obligations. Such party (a) has the requisite power and authority and the legal right to enter into this
Agreement and to perform its obligations hereunder; and (b) has taken all requisite action on its part to authorize the execution
and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered
on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with
its terms.

 

2.2.4Consents.
All necessary consents, approvals and authorizations of all governmental authorities and other persons or entities required to
be obtained by such party in connection with this Agreement have been obtained.

 

    	4

    	 

    

  

2.2.5No
Conflict. The execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a)
do not conflict with or violate any requirement of applicable laws, regulations or orders of governmental bodies; and (b) do not
conflict with, or constitute a default under, any contractual obligation of such party.

 

2.3DISCLAIMER
OF WARRANTIES. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN SECTION 2.1, IMPRIMIS MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS
OR IMPLIED, REGARDING THE LICENSED IP RIGHTS, OR ANY OTHER MATTER, INCLUDING WITHOUT LIMITATION, ANY REPRESENTATION OR WARRANTY
REGARDING VALIDITY, ENFORCEABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT.

 

	 	3.	license.

 

3.1Non-Exclusive
License Grants to ADF.

 

3.1.1On
the terms and conditions of this Agreement, Imprimis hereby grants to ADF a non-exclusive license under the Licensed Know-How
Rights and Licensed Patent Rights to formulate, make, use, offer for sale and sell the Products solely branded with the Licensed
Marks and formulated and dispensed by Qualified Pharmacies to end user customers in the Territory for use in the Field.

 

3.1.2On
the terms and conditions of this Agreement, Imprimis hereby grants to ADF a non-exclusive license to use the Licensed Marks solely
in the promotion, marketing and commercialization of the Products in the Territory for use in the Field as permitted hereunder.

 

3.1.3On
the terms and conditions of this Agreement, Imprimis hereby grants to ADF a non-exclusive license under the Licensed Copyrights
to reproduce, prepare derivative works, distribute copies, display and perform the subject matter thereof solely in the promotion,
marketing and commercialization of the Products in the Territory for use in the Field as permitted hereunder.

 

3.1.4ADF
shall have the right to grant sublicenses to Affiliates (without the right to grant further sublicenses with the prior express
written consent of Imprimis. Any such sublicense shall be subject and subordinate to the terms and conditions of this Agreement.
ADF shall cause each such Affiliate to fully comply with all terms and conditions of this Agreement applicable to ADF, and ADF
shall be liable for any and all breaches thereof by any such Affiliate.

 

3.1.5Except
as expressly set forth in this Agreement, ADF and its Affiliates shall not, directly or indirectly, (a) formulate, make, use,
offer for sale, sell or dispense the products specifically described on Exhibit A (as amended or restated from time to time by
mutual written agreement of the parties), or (b) use or exploit the Licensed IP Rights other than as expressly licensed hereunder.

 

    	5

    	 

    

  

3.2Conversion
to Exclusive License. Prior to December 31, 2015, the parties shall negotiate in good faith and attempt to reach mutual agreement
on the terms and conditions upon which ADF would have the option to convert the licenses hereunder to exclusive. Such terms and
conditions would include, without limitation, (a) diligence and market penetration conditions to convert, (b) annual diligence
and market growth conditions to maintain exclusivity, and (c) an annual license fee of $50,000 payable to Imprimis (one-half (1⁄2)
of which would be creditable against the royalties owing during such year).

 

3.3Cross
License to Imprimis. ADF hereby grants to Imprimis a royalty-free, perpetual, irrevocable, nonexclusive, worldwide license
(with the right to grant sublicenses) under the Supported Patent Rights for all uses. Imprimis shall use commercially reasonable
efforts to obtain a similar grantback license from any third party that enters into a license agreement with Imprimis for rights
to formulate, make, use, offer for sale and sell any Product, and if Imprimis is unable to obtain such a grantback license from
any such third party, then Imprimis shall not grant a sublicense to such third party under the license grant from ADF under this
Section 3.3, and any such sublicense granted by Imprimis to such third party shall be void.

 

3.4No
Implied Licenses. Only licenses and rights expressly granted herein shall be of legal force and effect. No license or other
right shall be created hereunder by implication, estoppel or otherwise.

 

	 	4.	financial
    terms.

 

4.1License
Fee. On the Effective Date, the ADF Parties, joint and severally, shall pay to Imprimis the nonrefundable and noncreditable
license fee of $10,000.

 

4.2Royalties.

 

4.2.1During
the applicable Royalty Term, the ADF Parties, jointly and severally, shall pay to Imprimis royalties on each unit of Product sold
by ADF, its sublicensees and their respective Affiliates equal to the greater of (a twenty percent (20%) of Sales for each such
unit, and (b)(i) fifty dollars ($50) for each such unit of an injectable Product, or (ii) a mutually agreed amount (to be determined
not less than ninety (90) days after the Effective Date by mutual written agreement of the parties after good faith negotiation)
for each such unit of a topical Product.

 

4.2.2If
ADF, its sublicensees or their respective Affiliates sells a Product to a third party who also purchases other products or services
from ADF, its sublicensees or their respective Affiliates, and ADF, its sublicensees or their respective Affiliates discounts
the purchase price of such Product to a greater degree than it generally discounts the price of its other products or services
to such customer, then in such case the Sales for the sale of such Product to such third party shall equal the arm’s length
price that third parties would generally pay for such Product alone when not purchasing any other product or service from ADF,
its sublicensee or their respective Affiliates. For purposes of this provision, “discounting” includes without limitation
establishing the list price at a lower-than-normal level, or providing credits, allowances, discounts, rebates, chargebacks or
other price reductions at a higher-than-normal level.

 

    	6

    	 

    

  

4.3Royalty
Reports.

 

4.3.1Within
thirty (30) days after the end of each calendar quarter, ADF shall furnish to Imprimis a written report showing in reasonably
specific detail (a) the gross invoiced sales price for each Product sold by ADF, its sublicensees and their respective Affiliates
during such calendar quarter and the calculation of Sales therefrom; (b) the calculation of the royalties, if any, which shall
have accrued based upon such Sales; (c) the exchange rates, if any, used in determining the amount of United States dollars; and
(d) the name of the prescribing physician or ordering party for each such Product.

 

4.3.2With
respect to sales of a Product invoiced in United States dollars, all such amounts shall be expressed in United States dollars.
With respect to sales of a Product invoiced in a currency other than United States dollars, all such amounts shall be expressed
both in the currency in which the sale is invoiced and in the United States dollar equivalent. The United States dollar equivalent
shall be calculated using the exchange rate (local currency per US$1) published in The Wall Street Journal, Western Edition,
under the heading “Currency Trading” on the last business day of the applicable calendar quarter. All royalties payable
hereunder shall be calculated based on Sales expressed in United States dollars.

 

4.3.3ADF
shall keep complete and accurate records in sufficient detail to properly reflect all gross sales and Sales and to enable the
royalties payable to be determined.

 

4.3.4All
royalties shown to have accrued by each royalty report provided under this Section 4.3 shall be payable on the date such royalty
report is due. Payment of royalties in whole or in part may be made in advance of such due date.

 

4.4Audits.
Upon the written request of Imprimis and not more than once in each calendar year, ADF shall permit an independent certified public
accounting firm of nationally recognized standing, selected by Imprimis and reasonably acceptable to ADF, at Imprimis’ expense,
to have access during normal business hours to such records of ADF as may be reasonably necessary to verify the accuracy of the
royalty reports hereunder for any year ending not more than thirty-six (36) months prior to the date of such request. If such
accounting firm concludes that additional royalties were owed during the audited period, ADF shall pay such additional royalties
within thirty (30) days of the date Imprimis delivers to ADF such accounting firm’s written report so concluding. The fees
charged by such accounting firm shall be paid by Imprimis; provided, however, if the audit discloses that the aggregate royalties
payable by ADF for such period are more than one hundred five percent (105%) of the royalties actually paid for such period, then
ADF shall pay the reasonable fees and expenses charged by such accounting firm. Imprimis shall treat all financial information
subject to review under this Section 4.4 as confidential, and shall cause its accounting firm to retain all such financial information
in confidence.

 

4.5No
Offsets, Credits or Deductions. Except as the parties otherwise mutually agree in writing, ADF shall make all payments hereunder
without offset, credit or deduction of any type whatsoever or for any reason.

 

    	7

    	 

    

  

4.6Payment
Method. All payments by ADF to Imprimis hereunder shall be in United States dollars in immediately available funds and shall
be made by wire transfer to such bank account as designated from time to time by Imprimis to ADF.

 

	 	5.	SPECIFIC
    OBLIGATIONS OF ADF.

 

5.1Responsibility.
On the terms and conditions of this Agreement, ADF shall be solely responsible, at its sole expense, for the formulation, making,
use, offering for sale and sale of the Product in the Territory.

 

5.2Specifications.
ADF, its sublicensees and their respective Affiliates shall formulate, make and use, offer for sale, sell and the Products solely
in accordance with the applicable Specifications.

 

5.3Compliance
with Laws and Quality Standards. ADF, its sublicensees and their respective Affiliates shall conduct all activities under
this Agreement or relating to Products in accordance with (a) all applicable laws and regulations, (b) all quality standards,
protocols and systems established by Imprimis from time to time therefor, and (c) the highest quality standards, protocols and
systems for sterile ophthalmic compounding formulations in the Territory.

 

5.4Diligence.
ADF shall use commercially reasonable efforts to formulate, make, use, offer for sale and sell the Products in the Territory,
and to meet the reasonably foreseeable market demand therefor. Without limiting the generality of the foregoing:

 

5.4.1ADF
shall employ and maintain a national commercial team (which shall include not less than the following full-time employees: three
(3) dedicated sales directors, one (1) reimbursement/billing manager, and one (1) customer service representative) primarily dedicated
to the promotion, marketing and sales of the Products in the Territory hereunder.

 

5.4.2ADF
shall promote, market and commercialize the Products throughout the Territory in each of the following four key market segments:
cataract surgeons, LASIK/refractive surgeons, general ophthalmologists, and optometrists.

 

5.4.3ADF
shall cause members of such national commercial team annually to attend relevant national and regional ophthalmology conferences,
such as conferences of the Canadian Ophthalmology Society.

 

5.4.4ADF
shall actively generate grass roots efforts (including by engaging the societies/advocacy groups and using social media) to facilitate
Dropless and LessDrops discussion.

 

5.4.5ADF
shall achieve and maintain a market share of not less than 10% to 15% of the relevant market in the Territory for such products
in the Territory on and after the first anniversary of the Effective Date.

 

A
breach of this Section 5.4 shall be a material breach of this Agreement.

 

    	8

    	 

    

  

5.5Marketing,
Promotion and Sales. ADF shall use only such marketing and other materials for the Products in the Territory as are expressly
approved in writing in advance by Imprimis, are consistent in all respects with positioning of such Products by Imprimis, include
all warnings and instructions applicable for the proper use of the Products, comply with all applicable laws and regulations in
the Territory, and do not contain any claims regarding a Product or its performance that ADF does not reasonably demonstrate are
supported by such Product or its performance. ADF shall not make any warranty or claim, express or implied, relating to any Product
other than those contained in any marketing materials provided by Imprimis to ADF or otherwise expressly authorized in writing
by Imprimis. ADF shall have the right to use, translate and make copies of marketing materials provided by Imprimis to ADF hereunder
to the extent reasonably necessary to perform its obligations under this Agreement and subject to the terms and conditions of
this Agreement. If Imprimis reasonably believes that any marketing or other materials for the Products for use in the Territory
fail to fully comply with the terms and conditions of this Agreement, Imprimis shall give written notice thereof and ADF immediately
shall cease to use such non-compliant materials.

 

5.6Claims,
Complaints and Incidents. ADF promptly shall notify Imprimis in writing of any claim, complaint or incident of which it becomes
aware relating to patient injury, death, or serious public health threat relating to a Product.

 

5.7Cost
of Approval of Sublicensees and Qualified Pharmacies. Imprimis shall invoice ADF for the reasonable costs and expenses incurred
or accrued by Imprimis in connection with any request to approve an Affiliate as a sublicensee or a compounding pharmacy facility
as a Qualified Pharmacy hereunder, and the ADF Parties jointly and severally shall pay Imprimis such costs and expenses within
thirty (30) days after the date of the applicable invoice.

 

	 	6.	MARKETING
    Committee.

 

6.1Membership.
The Marketing Committee shall comprise an equal number of representatives of Imprimis and of ADF, as determined by mutual agreement
of the parties. Each party shall appoint its representatives to the Marketing Committee from time to time, and may substitute
one or more of its representatives, in its sole discretion, effective upon written notice to the other party of such change.

 

6.2Purpose.
The purpose of the Marketing Committee shall be (a) to facilitate the exchange of information between the parties regarding the
promotion, marketing and sales of the Products hereunder, (b) to review and discuss the proposed marketing and other materials
for the Products in the Territory, (c) to discuss any issues relating to the promotion, marketing and sales of the Products hereunder.
The Marketing Committee shall have no authority to make decisions affecting this Agreement or the rights or obligations of the
parties hereunder, but may make proposed recommendations only.

 

6.3Meetings.
The Marketing Committee shall meet at least once quarterly and otherwise on an as needed basis (as mutually determined by the
parties). Such meetings shall be held on such dates and at such times and places as mutually agreed by the parties.

 

    	9

    	 

    

  

	 	7.	intellectual
    property rights.

 

7.1Patent
Rights.

 

7.1.1Imprimis
shall have the sole right, at its sole expense, to control the preparation, filing, prosecution, maintenance, enforcement and
defense of the Licensed Patent Rights. Imprimis shall consider in good faith the interests of ADF in so doing. ADF shall assist
Imprimis, upon request and at Imprimis’ sole expense, and to the extent commercially reasonable, in connection therewith.

 

7.1.2ADF
shall have the sole right, at its sole expense, to control the preparation, filing, prosecution, maintenance, enforcement and
defense of the Supported Patent Rights. ADF shall consider in good faith the interests of Imprimis in so doing.

 

7.2Copyrights.
ADF hereby acknowledges that Imprimis or a Third Party has claimed, or may claim, copyright protection with respect to certain
parts of the Products and the labels, inserts, studies, publications, promotional materials, and other materials related to the
Products. ADF shall not knowingly take any action which is in any way inconsistent with Imprimis’ or such Third Party’s
claim of copyright protection with respect to such items.

 

7.3Marks.
ADF shall use the Licensed Marks in accordance with such use restrictions provided from time to time by Imprimis. ADF shall not
use any Licensed Marks, or any word, title, expression, trademark, design or marking that is confusingly similar thereto, other
than in connection with the promotion, marketing and sale of the Products in the Territory on the terms and subject to the conditions
of this Agreement. Without limiting the generality of the foregoing, ADF shall not use any Licensed Marks, or any word, title,
expression, trademark, design or marking that is confusingly similar thereto, as part of its corporate or business name or in
any other manner whatsoever and shall not register any trade mark or trade name (including any company name) which is identical
to or confusingly similar to or incorporates the Imprimis Marks. Any goodwill associated with the Licensed Marks shall accrue
to the sole benefit of Imprimis.

 

	 	8.	CONFIDENTIALITY.

 

8.1Confidentiality.
During the term of this Agreement and for a period of five (5) years following the expiration or earlier termination hereof, each
party shall maintain in confidence the Confidential Information of the other party, shall not use or grant the use of the Confidential
Information of the other party except as expressly permitted hereby, and shall not disclose the Confidential Information of the
other party except on a need-to-know basis to such party’s directors, officers, employees and consultants, to the extent
such disclosure is reasonably necessary in connection with such party’s activities as expressly authorized by this Agreement.
To the extent that disclosure to any person is authorized by this Agreement, prior to disclosure, a party shall obtain agreement
of such person to hold in confidence and not disclose, use or grant the use of the Confidential Information of the other party
except as expressly permitted under this Agreement. Each party shall notify the other party promptly upon discovery of any unauthorized
use or disclosure of the other party’s Confidential Information.

 

    	10

    	 

    

  

8.2Terms
of Agreement. Neither party shall disclose any terms or conditions of this Agreement to any third party without the prior
consent of the other party; provided, however, that a party may disclose the terms or conditions of this Agreement, (a) on a need-to-know
basis to its legal and financial advisors to the extent such disclosure is reasonably necessary, and (b) to a third party in connection
with (i) an equity investment in such party, (ii) a merger, consolidation or similar transaction by such party, or (iii) the sale
of all or substantially all of the assets of such party. Notwithstanding the foregoing, prior to execution of this Agreement,
the parties have agreed upon the substance of information that can be used to describe the terms and conditions of this transaction,
and each party may disclose such information, as modified by mutual written agreement of the parties, without the consent of the
other party.

 

8.3Permitted
Disclosures. The confidentiality obligations under this Section 8 shall not apply to the extent that a party is required to
disclose information by applicable law, regulation, court order or rules of a stock exchange or automated quotation system; provided,
however, that such party shall provide advanced written notice thereof to the other party, consult with the other party with respect
to such disclosure and provide the other party sufficient opportunity to object to any such disclosure or to request confidential
treatment thereof (if applicable).

 

	 	9.	indemnification
    AND INSURANCE.

 

9.1By
ADF. The ADF Parties, jointly and severally, shall indemnify and hold harmless Imprimis, and its directors, officers, employees
and agents, from and against all losses, liabilities, damages and expenses, including reasonable attorneys’ fees and costs
(collectively, “Liabilities”), resulting from any claims, demands, actions or other proceedings by any third party
to the extent resulting from (a) the breach of any representation, warranty or covenant by ADF under this Agreement; (b) the use
of the Licensed IP Rights by ADF, its sublicensees or their respective Affiliates; (c) the formulation, making, use, offer for
sale or sale of a Product by or on behalf of ADF, its sublicensees or their respective Affiliates, customers or end-users; or
(d) the use of the Confidential Information of Imprimis by ADF, its sublicensees or their respective Affiliates.

 

9.2Procedure.
If Imprimis intends to claim indemnification under this Section 9, it shall promptly notify ADF in writing of any claim, demand,
action or other proceeding for which Imprimis intends to claim such indemnification, and ADF shall have the right to participate
in, and, to the extent ADF so desires, to assume the defense thereof with counsel mutually satisfactory to the parties; provided,
however, that the indemnitee shall have the right to retain its own counsel, with the fees and expenses to be paid by the ADF
Parties, if representation of such indemnitee by the counsel retained by ADF would be inappropriate due to actual or potential
differing interests between such indemnitee and any other party represented by such counsel in such proceeding. The obligations
of this Section 9 shall not apply to amounts paid in settlement of any claim, demand, action or other proceeding if such settlement
is effected without the consent of ADF, which consent shall not be withheld or delayed unreasonably. Imprimis, its employees and
agents, shall reasonably cooperate with ADF and its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by this Section 9.

 

    	11

    	 

    

  

9.3Insurance.
ADF shall maintain insurance, including comprehensive or commercial general liability and products liability insurance (contractual
liability included), with respect to its activities under this Agreement in such amounts and with such limits as reasonable and
customary in the industry, but with limits not less than the following: (a) each occurrence, one million dollars ($1,000,000);
(b) products/completed operations aggregate, five million dollars ($5,000,000); (c) personal and advertising injury, one million
dollars ($1,000,000); and (d) general aggregate (commercial form only), five million dollars ($5,000,000). ADF shall maintain
such insurance for so long as it continues its activities under this Agreement, and thereafter for so long as it customarily maintains
insurance for itself covering similar activities; provided, however, if such insurance is written on a claims-made form, it shall
continue for not less than three (3) years following termination or expiration of this Agreement.

 

	 	10.	TERM
    AND TERMINATION.

 

10.1Term.
This Agreement shall commence on the Effective Date and, unless earlier terminated pursuant to this Section 10, shall continue
in effect until the expiration of ADF’s obligation to pay royalties hereunder.

 

10.2Termination.

 

10.2.1If
a party has materially breached this Agreement, and such material breach shall continue for thirty (30) days after written notice
of such breach was provided to the breaching party by the nonbreaching party, the nonbreaching party shall have the right at its
option to terminate this Agreement effective at the end of such thirty (30) day period.

 

10.2.2If
ADF or any of its Affiliates Challenges any of the patent rights owned by or licensed to Imprimis or its Affiliates relating to
the Products, then unless, within thirty (30) days after written notice thereof by Imprimis, ADF withdraws or causes to be withdrawn
all such Challenges, this Agreement automatically shall terminate upon the expiration of such thirty (30) day period.

 

10.2.3ADF
may terminate this Agreement at any time upon ninety (90) days prior written notice to Imprimis.

 

10.3Effect
of Expiration or Termination.

 

10.3.1Expiration
or termination of this Agreement shall be without prejudice to any rights which shall have accrued to the benefit of a party prior
to such expiration or termination. Without limiting the foregoing, Sections 2.3, 3.1.5, 3.3, 3.4, 4.3, 4.4, 5.6, 6, 8, 9, 10.3
and 11 shall survive any expiration or termination of this Agreement.

 

10.3.2Except
as otherwise expressly set forth in this Agreement, promptly upon the expiration or earlier termination of this Agreement, each
party shall return to the other party all tangible items regarding the Confidential Information of the other party and all copies
thereof; provided, however, that each party shall have the right to retain one (1) copy for its legal files for the sole purpose
of determining its obligations hereunder.

 

    	12

    	 

    

  

10.3.3Following
the expiration or termination of this Agreement, ADF and its Affiliates shall not, directly or indirectly, (a) formulate, make,
use, offer for sale, sell or dispense the products specifically described on Exhibit A (as amended or restated from time to time
by mutual written agreement of the parties), or (b) use or exploit the Licensed IP Rights.

 

	 	11.	miscellaneous.

 

11.1Governing
Law. This Agreement shall be governed by, interpreted and construed in accordance with the laws of the State of California,
without regard to the conflicts of law principles thereof. Any legal action or other proceeding to resolve any dispute arising
from or relating to this Agreement shall be brought only in the courts of the State of California, located in San Diego County,
or the federal court of the United States of America, located in San Diego, California. Each party expressly consents to the exclusive
personal jurisdiction and venue of such courts for the purpose of any such legal action or other proceeding.

 

11.2Waiver.
No waiver by a party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed a
waiver as to any subsequent and/or similar breach or default.

 

11.3Assignment.
Neither this Agreement nor any right or obligation hereunder may be assigned or delegated, in whole or part, by either party without
the prior express written consent of the other; provided, however, that either party may, without the written consent of the other,
assign this Agreement and its rights and delegate its obligations hereunder in connection with the transfer or sale of all or
substantially all of its business, or in the event of its merger, consolidation, change in control or similar transaction. Any
permitted assignee shall assume all obligations of its assignor under this Agreement. Any purported assignment in violation of
this Section 11.3 shall be void.

 

11.4Independent
Contractors. The relationship of the parties hereto is that of independent contractors. The parties hereto are not deemed
to be agents, partners or Marketing venturers of the others for any purpose as a result of this Agreement or the transactions
contemplated thereby.

 

11.5Further
Actions. Each party shall execute, acknowledge and deliver such further documents and instruments and to perform all such
other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.

 

    	13

    	 

    

  

11.6Notices.
All requests and notices required or permitted to be given to the parties hereto shall be given in writing, shall expressly reference
the section(s) of this Agreement to which they pertain, and shall be delivered to the other party, effective on receipt, at the
appropriate address as set forth below or to such other addresses as may be designated in writing by the parties from time to
time during the term of this Agreement.

 

	 	If
    to Imprimis:	Imprimis
    Pharmaceuticals, Inc.	 
	 	 	12264 El Camino
    Real, Suite 350	 
	 	 	San Diego, California
    92130, U.S.A.	 
	 	 	Attn: Gary W.
    Seelhorst	 
	 	 	 	 
	 	With a copy to:	Morrison &
    Foerster LLP	 
	 	 	12531 High Bluff
    Drive, Suite 100	 
	 	 	San Diego, California
    92121, U.S.A.	 
	 	 	Attention: Mark
    R. Wicker	 
	 	 	 	 
	 	If to the ADF
    Parties:	Advance Dosage
    Forms, Inc.	 
	 	 	3700 St-Patrick,
    suite 240	 
	 	 	Montreal, Quebec,
    H4E 1A, Canada	 
	 	 	Attn: John Di
    Genova	 
	 	 	 	 
	 	With a copy to:	John Di Genova	 
	 	 	5858 Côte
    des Neiges , suite 400,	 
	 	 	Montreal, Quebec
    H3S 1Z1, Canada	 

 

11.7No
Consequential Damages. IN NO EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF
THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, INCLUDING WITHOUT LIMITATION LOST PROFITS ARISING FROM OR RELATING TO
ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 11.7 IS INTENDED TO LIMIT OR RESTRICT
THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTION 9 ABOVE.

 

11.8Imprimis
In-Licenses. Notwithstanding anything to the contrary in this Agreement, the grant of rights by Imprimis under this Agreement
shall be subject to and limited in all respects by the terms of the applicable Imprimis In-License(s) pursuant to which Imprimis
acquired Licensed IP Rights, and all rights or sublicenses granted under this Agreement shall be limited to the extent that Imprimis
may grant such rights and sublicenses under such Imprimis In-Licenses.

 

11.9Complete
Agreement. This Agreement constitutes the entire agreement between the parties regarding the subject matter hereof, and all
prior representations, understandings and agreements regarding the subject matter hereof, either written or oral, expressed or
implied, are superseded and shall be and of no effect.

 

11.10Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed to be an original and together shall be deemed to
be one and the same agreement.

 

11.11United
States Dollars. Except as otherwise expressly specified herein, all amounts specified herein are expressed in United States
dollars.

 

11.12Headings.
The captions to the several sections hereof are not a part of this Agreement, but are included merely for convenience of reference
only and shall not affect its meaning or interpretation.

 

    	14

    	 

    

  

IN
WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly-authorized representatives as
of the Effective Date.

 

	 	IMPRIMIS
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/
    Mark L. Baum 
	 	 	 
	 	Name:	Mark
    L. Baum 
	 	 	 
	 	Title:	CEO 
	 	 	 
	 	ADVANCED
    DOSAGE FORMS, INC.
	 	 	 
	 	By:	/s/
    John Di Genova
	 	 	 
	` 	Name:	John
    Di Genova
	 	 	 
	 	Title:	President
	 	 	 
	 	/s/ John DiGenova
	 	JOHN
    DIGENOVA

 

    	15

    	 

    

  

EXHIBIT
A

PRODUCTS

 

	Short
    Name	 	Long
    Name	 	Notes
	 	 	 	 	 
	Injectable	 	 	 	 
	 	 	 	 	 
	Tri-Moxi	 	triamcinolone
    acetonide 15 mg/mL, moxifloxacin hydrochloride 1 mg/mL	 	single use 1 mL
    vial
	 	 	 	 	 
	Tri-Moxi-Vanc	 	triamcinolone
    acetonide 15 mg/mL, moxifloxacin hydrochloride 1 mg/mL, vancomycin 10 mg/mL	 	single use 1 mL
    vial
	 	 	 	 	 
	Dex-Moxi	 	dexamethasone
    sodium phosphate 1 mg/mL, moxifloxacin hydrochloride 5 mg/mL	 	single use 1 mL
    vial
	 	 	 	 	 
	Topical	 	 	 	 
	 	 	 	 	 
	Pred-Moxi Drops	 	prednisolone acetate
    1%, moxifloxacin hydrochloride 0.5%	 	3 mL sterile preservative
    free ophthalmic drops
	 	 	 	 	 
	Tri-Moxi Drops	 	triamcinolone
    acetonide 1.5%, moxifloxacin hydrochloride 0.5%	 	3 mL sterile preservative
    free ophthalmic drops
	 	 	 	 	 
	Pred-Ketor Drops	 	prednisolone acetate
    1%, ketorolac tromethamine 0.4%	 	3 mL sterile preservative
    free ophthalmic drops
	 	 	 	 	 
	Pred-Moxi-Ketor
    Drops	 	prednisolone acetate
    1%, moxifloxacin hydrochloride 0.5%, ketorolac tromethamine 0.4%	 	3 mL sterile preservative
    free ophthalmic drops
	 	 	 	 	 
	Pred-Moxi Drops	 	prednisolone acetate
    1%, moxifloxacin hydrochloride 0.5%	 	6 mL sterile ophthalmic
    drops w/preservatives
	 	 	 	 	 
	Pred-Ketor Drops	 	prednisolone acetate
    1%, ketorolac tromethamine 0.4%	 	6 mL sterile ophthalmic
    drops w/preservatives
	 	 	 	 	 
	Pred-Moxi-Ketor
    Drops	 	prednisolone acetate
    1%, moxifloxacin hydrochloride 0.5%, ketorolac tromethamine 0.4%	 	6 mL sterile ophthalmic
    drops w/preservatives

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]